This study evaluates the efficacy of maintenance durvalumab in oesophagogastric adenocarcinoma (OGA) using the Xerna™ TME RNA assay. The assay classifies tumors into four subtypes: Angiogenic (A), Immune Active (IA), Immune Desert (ID), and Immune Suppressed (IS). Analysis of 205 patients revealed that those with high immune scores (IA + IS) showed improved survival with durvalumab compared to active surveillance, particularly in PD-L1 CPS ≥5 patients. These findings suggest that the Xerna™ TME panel could enhance patient selection for immune checkpoint inhibitors in HER2-negative OGA.
Published at ESMO 2022.
C. Fong1, S. Iyer2, L. Potts1, C. Peckitt1, S. Cromarty1, C. Saffery1, S. Kidd1, T. Rana1, L. Ausec3, A. Gregorc3, D. Pointing3, M. Gombert4, K. von Loga1,L. Benjamin2, N. Starling1, T. Waddell5, R. Petty6, M. Uhlik2, I. Chau1, D. Cunningham1
1 The Royal Marsden Hospital NHS Foundation Trust, London and Sutton, United Kingdom
2 OncXerna Therapeutics Inc., Waltham, United States of America
3 Genialis Inc., Boston, United States of America
4 QIAGEN GmbH, Hilden, Germany
5 The Christie NHS Foundation Trust, Manchester, United Kingdom
6 Ninewells Hospital, Dundee, United Kingdom
